20种肿瘤化疗药物对Treg细胞增殖的影响

doi:10.16352/j.issn.1001-6325.2023.10.1518

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (10): 1518-1521.doi: 10.16352/j.issn.1001-6325.2023.10.1518

20种肿瘤化疗药物对Treg细胞增殖的影响

黄薇, 凌睿云, 高乐欣, 唐文, 钱令波, 陈峰阳^*

杭州医学院基础医学与法医学院, 浙江杭州 310053

收稿日期:2023-01-05 修回日期:2023-05-30 出版日期:2023-10-05 发布日期:2023-10-05
通讯作者: *cfy@hmc.edu.cn
基金资助:
健康浙江专项计划(YS2022003);国家级大学生创新创业训练计划(202213023018);浙江省大学生创新创业训练计划(S202213023054)

Effects of twenty kinds of chemotherapeutic agents on the proliferation of Treg cells

HUANG Wei, LING Ruiyun, GAO Lexin, TANG Wen, QIAN Lingbo, CHEN Fengyang^*

School of Basic Medical Sciences & Forensic Medicine, Hangzhou Medical College, Hangzhou 310053, China

Received:2023-01-05 Revised:2023-05-30 Online:2023-10-05 Published:2023-10-05
Contact: *cfy@hmc.edu.cn

摘要/Abstract

摘要： 目的观察20种肿瘤化疗药物对调节性T细胞(Treg)增殖的影响。方法选取20种常见的肿瘤化学治疗(化疗)药物,采用IL-2诱导Treg细胞增殖,通过CellTrace标记和流式细胞测量术测定。结果用12种化疗药在无细胞毒性的浓度下作用后,CD4⁺T 细胞中Foxp3⁺ Treg细胞比例明显减少,分裂的Treg细胞数明显降低(P＜0.05)。结论 12种化疗药物,其中包括3个影响微管蛋白药物、3个干扰转录和RNA合成的药物及2个拓扑异构酶抑制剂能显著抑制Treg细胞的增殖。

关键词: 肿瘤免疫, 化学治疗, Treg细胞

Abstract: Objective To observe the effects of 20 chemotherapeutic agents on the proliferation of Treg cells. Methods Twenty agents used in routine chemotherapy were selected and assayed on IL-2- induced Treg cell proliferation through CellTrace labeling and flow cytometry. Results After treatment with 12 chemotherapeutic agents at non-cytotoxic concentration, the proportion as well as the number of Foxp3⁺Treg cells in CD4⁺ T cells were significantly reduced. Conclusions Twelve chemotherapeutic agents including 3 tubulin interfering agents, 3 transcription and RNA synthesis interfering agents and 2 topoisomerase inhibitors inhibited the proliferation of Treg cells.

Key words: cancer immunity, chemotherapy, Treg cell

中图分类号:

R979.1

黄薇, 凌睿云, 高乐欣, 唐文, 钱令波, 陈峰阳. 20种肿瘤化疗药物对Treg细胞增殖的影响[J]. 基础医学与临床, 2023, 43(10): 1518-1521.

HUANG Wei, LING Ruiyun, GAO Lexin, TANG Wen, QIAN Lingbo, CHEN Fengyang. Effects of twenty kinds of chemotherapeutic agents on the proliferation of Treg cells[J]. Basic & Clinical Medicine, 2023, 43(10): 1518-1521.

参考文献 12

[1]	Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression-implications for anticancer therapy[J]. Nat Rev Clin Oncol, 2019, 16: 356-371.
[2]	Minohara K, Imai M, Matoba T, et al. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer[J]. Cancer Sci, 2023,114:1256-1269.
[3]	Mehraj U, Dar AH, Wani NA, et al. Tumor microenvironment promotes breast cancer chemoresistance[J]. Cancer Chemother Pharmacol, 2021,87:147-158.
[4]	Galluzzi L, Buqué A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anti-cancer agents[J]. Cancer Cell,2015,28:690-714.
[5]	Li P, Chen F, Zheng J, et al. Cyclophosphamide abrogates the expansion of CD4+Foxp3+ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas[J]. Cancer Biol Med, 2021,18:1010-1020.
[6]	Dees S, Ganesan R, Singh S, et al. Regulatory T cell targeting in cancer: emerging strategies in immunotherapy[J]. Eur J Immunol, 2021,51:280-291.
[7]	Eriksson E, Wenthe J, Irenaeus S, et al. Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer[J]. J Transl Med, 2016,14:282.doi:10.1186/s12967-016-1037-z.
[8]	Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer[J]. J Immunol Res, 2014,2014:286170.doi: 10.1155/2014/286170.doi: 10.1155/2014/286170.
[9]	Zhang L, Dermawan K, Jin M, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy[J]. Clin Immunol, 2008,129:219-229.
[10]	Kashima H, Momose F, Umehara H, et al. Epirubicin, identified using a novel luciferase reporter assay for Foxp3 inhibitors, inhibits regulatory T cell activity[J]. PLoS One, 2016,11:e0156643.doi: 10.1371/journal.pone.0156643.
[11]	Ning T, Li J, He Y, et al. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer[J]. Mol Ther, 2021,29:2723-2736.
[12]	Ye C, Brand D, Zheng SG. Targeting IL-2: an unex-pected effect in treating immunological diseases [J]. Signal Transduct Target Ther, 2018,3:2.doi: 10.1038/s41392-017-0002-5.

20种肿瘤化疗药物对Treg细胞增殖的影响

Effects of twenty kinds of chemotherapeutic agents on the proliferation of Treg cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 8

编辑推荐

Metrics

本文评价

[1]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[2]	邓娟, 王秀芳, 孙瑞青. 汉黄芩素促进自身免疫性肝炎模型大鼠Th17/Treg细胞平衡[J]. 基础医学与临床, 2024, 44(1): 77-83.
[3]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[4]	杜风, 陈翌阳, 张楠, 徐俊玄, 宁婷婷, 朱圣韬, 张澍田. FOXL2NB在结直肠癌中的表达和临床意义[J]. 基础医学与临床, 2023, 43(6): 909-915.
[5]	庄志诚, 官国先. 铁死亡在结直肠癌治疗中的作用[J]. 基础医学与临床, 2023, 43(1): 174-177.
[6]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[7]	何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇. 环状RNA在乳腺癌中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 507-511.
[8]	鞠晓红王艾琳顾颜春. 脐带血来源的树突状细胞体外诱导抗肿瘤效果的研究[J]. 基础医学与临床, 2006, 26(2): 174-174.